Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M98,196Revenue (TTM) $M17,618Net Margin (%)16.3Altman Z-Score5.8
Enterprise Value $M100,441EPS (TTM) $1.7Operating Margin %16.3Piotroski F-Score4
P/E(ttm)34.5Beneish M-Score-1.9Pre-tax Margin (%)21.8Higher ROA y-yY
Price/Book6.610-y EBITDA Growth Rate %-3.5Quick Ratio1.4Cash flow > EarningsN
Price/Sales5.65-y EBITDA Growth Rate %-18.4Current Ratio1.6Lower Leverage y-yN
Price/Free Cash Flow717y-y EBITDA Growth Rate %41.7ROA % (ttm)9.0Higher Current Ratio y-yN
Dividend Yield %2.6PEG--ROE % (ttm)19.5Less Shares Outstanding y-yN
Payout Ratio %88.0Shares Outstanding M1,671ROIC % (ttm)12.6Gross Margin Increase y-yN

Gurus Latest Trades with BMY

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
BMYRonald Muhlenkamp 2016-06-30 Reduce-0.8%$63.88 - $74.29
($70.56)
$ 58.77-17%Reduce -14.54%181,340
BMYVanguard Health Care Fund 2016-06-30 Reduce-0.35%$63.88 - $74.29
($70.56)
$ 58.77-17%Reduce -5.23%45,257,309
BMYT Rowe Price Equity Income Fund 2016-06-30 Reduce-0.21%$63.88 - $74.29
($70.56)
$ 58.77-17%Reduce -17.52%3,325,000
BMYMario Gabelli 2016-06-30 Reduce-0.01%$63.88 - $74.29
($70.56)
$ 58.77-17%Reduce -5.26%619,627
BMYKeeley Asset Management Corp 2016-06-30 Buy 0.01%$63.88 - $74.29
($70.56)
$ 58.77-17%New holding2,960
BMYKen Fisher 2016-06-30 Add$63.88 - $74.29
($70.56)
$ 58.77-17%Add 1.89%648,107
BMYRon Baron 2016-06-30 Add$63.88 - $74.29
($70.56)
$ 58.77-17%Add 1.85%114,941
BMYFirst Eagle Investment 2016-06-30 Reduce$63.88 - $74.29
($70.56)
$ 58.77-17%Reduce -10.92%11,529
BMYDodge & Cox 2016-06-30 Reduce$63.88 - $74.29
($70.56)
$ 58.77-17%Reduce -1.77%72,158
BMYVanguard Health Care Fund 2016-03-31 Add0.21%$58.87 - $68.79
($63.1)
$ 58.77-7%Add 3.29%47,754,809
BMYT Rowe Price Equity Income Fund 2016-03-31 Reduce-0.15%$58.87 - $68.79
($63.1)
$ 58.77-7%Reduce -10.82%4,031,100
BMYKen Fisher 2016-03-31 Add0.07%$58.87 - $68.79
($63.1)
$ 58.77-7%Add 371.85%636,060
BMYRon Baron 2016-03-31 Buy 0.04%$58.87 - $68.79
($63.1)
$ 58.77-7%New holding112,848
BMYMario Gabelli 2016-03-31 Add0.01%$58.87 - $68.79
($63.1)
$ 58.77-7%Add 2.29%654,005
BMYKahn Brothers 2016-03-31 Add0.01%$58.87 - $68.79
($63.1)
$ 58.77-7%Add 1.90%28,583
BMYRonald Muhlenkamp 2016-03-31 Add0.01%$58.87 - $68.79
($63.1)
$ 58.77-7%Add 0.21%212,200
BMYRuane Cunniff 2016-03-31 Sold Out $58.87 - $68.79
($63.1)
$ 58.77-7%Sold Out0
BMYDodge & Cox 2016-03-31 Reduce$58.87 - $68.79
($63.1)
$ 58.77-7%Reduce -5.16%73,458
BMYT Rowe Price Equity Income Fund 2015-12-31 Reduce-0.26%$59.88 - $70.71
($66.18)
$ 58.77-11%Reduce -18.01%4,520,000
BMYVanguard Health Care Fund 2015-12-31 Add0.12%$59.88 - $70.71
($66.25)
$ 58.77-11%Add 1.95%46,232,449
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

BMY is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


BMY: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
ANDREOTTI LAMBERTODirector 2016-08-25Sell23,200$59.170.02view
ANDREOTTI LAMBERTODirector 2016-07-08Sell23,200$74.45-20.51view
ANDREOTTI LAMBERTODirector 2016-06-28Sell23,200$72.14-17.97view
Elicker John ESVP, Public Affairs & IR 2016-06-14Sell11,820$72.69-18.59view
Bancroft Charles AEVP & CFO 2016-05-20Sell30,201$70.79-16.4view
Caldarella Joseph CSVP & Controller 2016-05-16Sell3,519$72.47-18.34view
LEUNG SANDRAEVP, General Counsel 2016-05-06Sell72,544$70.39-15.93view
ANDREOTTI LAMBERTODirector 2016-05-05Sell23,200$70.54-16.1view
Caforio GiovanniCEO 2016-05-03Sell34,594$71.31-17.01view
Nielsen AnneChief Compliance & Ethics Off 2016-05-02Sell28,451$71.88-17.67view

Press Releases about BMY :

Quarterly/Annual Reports about BMY:

News about BMY:

Articles On GuruFocus.com
Merck Offers Value and Steady Dividend Growth Aug 24 2016 
Spiros "Sig" Segalas' Capital Appreciation Fund 2nd Quarter Commentary Aug 18 2016 
Bristol-Myers Squibb Makes a Good Investment Aug 16 2016 
Eaton Vance Worldwide Health Sciences Fund 2nd Quarter Commentary Aug 04 2016 
Vanguard Sold Shares in 7 of Top 10 Quarterly Transactions Aug 02 2016 
Bristol-Myers a Strong Biopharma Pick Jul 25 2016 
Ken Fisher's Best Investments: Credicorp, Ambev, Tata Motors Jul 11 2016 
Baron Funds Comments on Bristol-Myers Squibb May 23 2016 
Baron Funds Comments on Bristol-Myers Squibb Company May 06 2016 
John Burbank Raises Stake in Microsoft Mar 02 2016 

More From Other Websites
Lung cancer doctors eye Merck's Keytruda over Bristol's Opdivo Aug 25 2016
Lung cancer doctors eye Merck's Keytruda over Bristol's Opdivo Aug 25 2016
How Did Bristol-Myers Squibb Fare in 2Q16? Aug 24 2016
Bristol-Myers Squibb and Pfizer to Present New Eliquis (apixaban) Analyses at ESC Congress 2016 Aug 23 2016
Bristol-Myers Squibb and Pfizer to Present New Eliquis (apixaban) Analyses at ESC Congress 2016 Aug 23 2016
Bristol-Myers Squibb and Pfizer to Present New Eliquis (apixaban) Analyses at ESC Congress 2016 Aug 23 2016
Allied Minds, Bristol-Myers Squibb to progress first drug to preclinical trials Aug 22 2016
How Did Bristol-Myers Squibb’s Oncology Segment Perform in 2Q16? Aug 22 2016
Bristol-Myers Squibb Stock Will Bounce Back -- Here's How You Can Profit Aug 22 2016
[$$] The Profit and Peril of Cancer Drugs Aug 21 2016
5 Trade Ideas for Monday: Bank of America, Bristol-Myers, DuPont, Halliburton and Mylan Aug 21 2016
Curbing Excessive Exuberance May be Premature Aug 21 2016
How Does Bristol-Myers Squibb’s Valuation Compare to Peers? Aug 19 2016
[$$] The Profit and Peril of Cancer Drugs Aug 19 2016
ETF’s with exposure to Bristol-Myers Squibb Co. : August 19, 2016 Aug 19 2016
Bristol-Myers Squibb attracts upside bets Aug 17 2016
Mirror Image: Bristol-Myers Loss Is Merck's Potential Gain Aug 16 2016
Bristol-Myers Squibb (BMY) Stock Falls, Bernstein: Failed Trial Impact to Persist Aug 15 2016
Bristol-Myers to Reacquire Rights to Oncology Drug in Asia Aug 15 2016
Bavarian Nordic Announces Drug Supply Agreement with Bristol-Myers Squibb for NSCLC Clinical Study Aug 15 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)